PUBLISHER: The Business Research Company | PRODUCT CODE: 1945289
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945289
Hemostatic agents are specialized substances designed to assist the body's natural blood clotting process by controlling and stopping bleeding. They work by interacting with different components of the coagulation system to promote the formation of a stable clot at the site of vascular injury.
The primary types of hemostatic agents include thrombin-based, gelatin-based, collagen-based, oxidized regenerated cellulose-based, combination hemostats, fibrin sealants, and others. Thrombin-based hemostats use thrombin, a natural blood enzyme, to quickly halt bleeding by accelerating clot formation. These agents are used in trauma care, cardiovascular surgery, general surgery, plastic surgery, orthopedic surgery, neurosurgery, and more, serving end users such as hospitals, surgical centers, nursing homes, and others.
Tariffs have influenced the hemostatic agents market by raising costs for imported raw materials such as collagen, gelatin, and recombinant proteins. Segments like fibrin sealants, combination hemostats, and oxidized regenerated cellulose-based products are most affected, particularly in regions such as North America and Asia-Pacific where import dependence is high. This has increased production costs and affected supply chain efficiency. On the positive side, tariffs have encouraged domestic manufacturing, local sourcing of raw materials, and innovation in multi-agent hemostatic formulations.
The hemostatic agents market research report is one of a series of new reports from The Business Research Company that provides hemostatic agents market statistics, including hemostatic agents industry global market size, regional shares, competitors with a hemostatic agents market share, detailed hemostatic agents market segments, market trends and opportunities, and any further data you may need to thrive in the hemostatic agents industry. This hemostatic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hemostatic agents market size has grown strongly in recent years. It will grow from $4.42 billion in 2025 to $4.66 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to limited variety of hemostatic agents, reliance on traditional thrombin and gelatin products, increasing number of surgical procedures, growing hospital infrastructure, awareness of blood loss management.
The hemostatic agents market size is expected to see strong growth in the next few years. It will grow to $5.71 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to development of recombinant and sprayable fibrin sealants, expansion in minimally invasive and orthopedic surgeries, rising demand for multi-agent and combination hemostats, increased adoption in plastic and neurosurgery applications, regulatory emphasis on sterility and biocompatibility. Major trends in the forecast period include rising demand for advanced hemostatic agents in surgical procedures, increasing adoption of combination and multi-agent hemostats, growth in fibrin sealants and biologically derived products, expansion of hemostats use in trauma and cardiovascular surgeries, enhanced focus on safety, sterility, and regulatory compliance.
The rising number of surgical procedures is anticipated to drive the growth of the hemostatic agents market in the coming years. Surgical procedures involve medical interventions carried out by healthcare professionals using specialized tools to treat, repair, or remove parts of the body for health-related purposes. The increase in surgical procedures is primarily due to the growing prevalence of chronic conditions, which often require surgical intervention to manage health issues and enhance patient outcomes. Hemostatic agents play a crucial role in surgeries, as they help control bleeding rapidly, minimizing blood loss and improving visibility in the surgical area for more precise operations. For example, in October 2025, data from the UK Health Security Agency (UKHSA), a UK-based national public health organization, indicated that during the 2023-24 period, 135,619 operations were reported, with 1,276 surgical site infections (SSIs) identified during inpatient care or readmission, reflecting an 8.4% rise in submissions compared to the previous year. Hence, the growing number of surgical procedures is fueling the expansion of the hemostatic agents market.
Key players in the hemostatic agents market are developing innovative products, such as collagen-based hemostats, designed to provide rapid and effective bleeding control and tissue sealing in both open and minimally invasive surgeries. Collagen-based hemostats consist of purified collagen materials that aid hemostasis by enhancing the body's natural clotting at wound or incision sites. For instance, in March 2025, Baxter, a US healthcare company, introduced HEMOPATCH Sealing Hemostat, an absorbable collagen-based pad. This advanced pad features a dual-action system that combines a collagen matrix with an NHS-PEG layer, which forms a hydrogel when it contacts moisture, enabling fast sealing of bleeding areas. It adheres strongly to wet tissues, making it effective in both open and minimally invasive surgical procedures where other agents may fall short. The patch achieves hemostasis in less than two minutes without requiring temperature-controlled storage or special preparation, simplifying surgical workflows. It naturally dissolves within 6 to 8 weeks and can be stored at room temperature for up to three years, meeting critical clinical and storage needs.
In May 2025, Merit Medical Systems Inc., a US medical device manufacturer, acquired Biolife Delaware LLC for an undisclosed sum. This acquisition positions Merit to offer a wider range of products that enhance consistency and efficiency in post-procedure care. It also strengthens Merit's portfolio with specialized hemostatic solutions suitable for various clinical applications, including bleeding management from vascular closures and indwelling catheters. Biolife Delaware LLC is a US-based producer of hemostatic agents.
Major companies operating in the hemostatic agents market are Pfizer Inc., Johnson & Johnson Services Inc., Becton Dickinson & Co., CSL Ltd., Baxter International Inc., Teleflex Inc., Integra LifeSciences Holdings Corp., Gelita Medical, Artivion Inc., B. Braun Melsungen AG, Advanced Medical Solutions Group Plc, Z-Medica, Marine Polymer Technologies Inc., MedTrade Products Ltd., Samyang Holdings Corp., Vascular Solutions Pc, BioCer Entwicklungs GmbH, Starch Medical Inc., Arch Therapeutics Inc., Medcura Inc., Biom'Up SAS.
North America was the largest region in the hemostatic agents market in 2025. The regions covered in the hemostatic agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the hemostatic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The hemostatic agents market consists of sales of chitosan-based hemostats, flowable hemostats, synthetic polymer-based hemostats, topical absorbable hemostats, and adhesive hemostatic films. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hemostatic Agents Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses hemostatic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for hemostatic agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemostatic agents market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.